Higher-dose firmonertinib after stable disease on initial treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a higher dose of the targeted pill firmonertinib (160 mg) can better control advanced lung cancer in people who have a specific EGFR mutation and whose disease remained stable after a lower dose for 8 weeks. The goal is to see if the higher dose improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of non-small cell lung cancer that is advanced or has spread, and it has a specific EGFR gene change (exon 19 deletion or L858R).
- You have not had any prior treatment for advanced lung cancer.
- You were treated with firmonertinib (80 mg daily) for 8 weeks and your disease stayed stable (didn't grow or shrink significantly).
- You have measurable tumors (at least one that can be seen on scans).
- You are generally well enough, with adequate organ function, and can care for yourself (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy pill (firmonertinib) given before and after surgery for stage II–III lung adenocarcinoma that has an EGFR mutation. The goal is to see if this approach can shrink the tumor before surgery and reduce the chance of cancer coming back.
This trial tests a new targeted pill (Firmonertinib) combined with standard chemotherapy for stage III lung cancer that cannot be removed by surgery. It is for people with a specific EGFR mutation, and the goal is to see if the combo helps shrink or control the cancer.
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.